FindTrial
Sign In

Evaluation of inflammation, bacterial concentration and lung strength in children and adolescents with Cystic Fibrosis and the effects of Curcumin supplementation

Evaluation of markers, microbiological and functions of children and adolescents with Cystic Fibrosis and the effects of Curcumin supplementation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-8gmn4w
Enrollment
Unknown
Registered
2020-01-27
Start date
2019-10-15
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic fibrosis

Interventions

Experimental group: 18 children and adolescents with Cystic Fibrosis will receive 500 mg of Curcumin. Control group: 18 children and adolescents will receive 500 mg of placebo. Subjects were randomly
Dietary supplement
D02.455.326.146.485.222.222

Sponsors

Izabela Zibetti de Albuquerque
Lead Sponsor
Hospital das Clínicas da Universidade Federal de Goiâs
Collaborator

Eligibility

Age
4 Years to 18 Years

Inclusion criteria

Inclusion criteria: Subjects with Cystic Fibrosis; age between 04 and 18 years

Exclusion criteria

Exclusion criteria: Failure to perform spirometry; forced expiratory volume in the first second less than or equal to 40% of predicted

Design outcomes

Primary

MeasureTime frame
It is expected to reduce the blood concentration of interleukin 6 by 40% as assessed by flow cytometry—

Secondary

MeasureTime frame
It is expected to increase lung function by 15% as assessed by spirometry;It is expected to reduce the concentration of neutrophil elastase in the induced sputum by 20% as assessed by centrifugation, filtration and drying and microscopic analysis—

Countries

Brazil

Contacts

Public ContactIzabela Albuquerque

Hospital das Clínicas da Universidade Federal de Goiâs

zibetti.izabela@gmail.com+55-62-984177469

Outcome results

None listed

Source: REBEC (via WHO ICTRP)